

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20201 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/016,371	12/10/2001	Ian R. Reid	HO-P02194US0	6234	
26271 . 7.	590 03/21/2003				
FULBRIGHT & JAWORSKI, LLP			EXAMINER		
1301 MCKINN SUITE 5100			BAHAR, N	BAHAR, MOJDEH	
HOUSTON, TX 77010-3095			ART UNIT	PAPER NUMBER	
			1617		
			DATE MAILED: 03/21/2003	5	

Please find below and/or attached an Office communication concerning this application or proceeding.

<i>*</i>	Application No.	Applicant(s)			
	10/016,371	REID, IAN R.			
Office Action Summary	Examiner	Art Unit			
	Mojdeh Bahar	1617			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a repl If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, ma by within the statutory minimum o will apply and will expire SIX (6) e, cause the application to becom	y a reply be timely filed thirty (30) days will be considered timely. MONTHS from the mailing date of this communication. e ABANDONED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on					
, <u> </u>	nis action is non-final.				
 Since this application is in condition for allow closed in accordance with the practice under Disposition of Claims 					
4)⊠ Claim(s) <u>1-21</u> is/are pending in the application	٦.				
4a) Of the above claim(s) is/are withdra					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.	•				
8) Claim(s) 1-21 are subject to restriction and/or	election requirement.				
Application Papers	·				
9)☐ The specification is objected to by the Examine	er.				
10) The drawing(s) filed on is/are: a) acce	pted or b) objected to	by the Examiner.			
Applicant may not request that any objection to the	*				
11)☐ The proposed drawing correction filed on	_ is: a)	disapproved by the Examiner.			
If approved, corrected drawings are required in re	•				
12) The oath or declaration is objected to by the Ex	kaminer.				
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority document	ts have been received i	n Application No			
 3. Copies of the certified copies of the prio application from the International Bu * See the attached detailed Office action for a list 	ireau (PCT Rule 17.2(a)).			
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) The translation of the foreign language pro	ovisional application ha	s been received.			
Attachment(s)	p. 10.11. a 11001 00 0.0				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 Notice	ew Summary (PTO-413) Paper No(s) · of Informal Patent Application (PTO-152)			

Application/Control Number: 10/016,371

Art Unit: 1617

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-9, 11-15 and 17-21, drawn to a method of increasing HDL in a post menopausal woman by administering calcium citrate, classified in class 424, subclass 439.
- II. Claims 10 and 16, drawn to a pharmaceutical/dietary composition comprising calcium citrate, classified in class 424, subclass 439.

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case HDL can be increased through physical exercise.

Applicant is advised that in order for the reply to this requirement to be complete it must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/016,371

Art Unit: 1617

5:00 p.m.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mojdeh Bahar whose telephone number is (703) 305-1007. The examiner can normally be reached on (703) 305-1007 from Monday to Friday from 9:00 a.m. to

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (703) 305-1877. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Mojdeh Bahar Patent Examiner March 18, 2003

SREENI PADMANABHAN
PRIMARY EXAMINER

3 17 03

Page 3